Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OR51E2 | Q9H255 | 2/20 | 0.33 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.33 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.30 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15756799 | 1.00 | OR51E2 (0.33) | OR51E2GLRA1SLC6A9GAASLC1A1 | |
| SCHEMBL8960944 | 0.82 | FFAR4 (0.39) | OR51E2 | |
| SCHEMBL3396664 | 0.80 | SLC7A5 (0.39) | GAASLC1A1USP2SLCO1B1 | |
| SCHEMBL29349420 | 0.80 | PTGS1 (0.39) | OR51E2GLRA1SLC6A9 | |
| SCHEMBL7790458 | 0.80 | PTGS1 (0.39) | OR51E2GLRA1SLC6A9 | |
| SCHEMBL15756829 | 0.80 | GABRR1 (0.38) | OR51E2GLRA1SLC6A9GABRR1LMNA | |
| SCHEMBL2950122 | 0.78 | DPP4 (0.33) | GAA | |
| SCHEMBL4097963 | 0.78 | USP2 (0.32) | USP2SLCO1B1 | |
| SCHEMBL15757064 | 0.77 | SLC7A5 (0.43) | GAASLC1A1GABRR1LMNA | |
| SCHEMBL4299640 | 0.75 | GSR (0.48) | GABRR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076285-B2 | Lysobactin amides | AICURIS GMBH & CO. KG (DE) | 2011-12-13 | — | — | US | disclosed |
| US-20090203582-A1 | LYSOBACTIN AMIDES | BAYER HEALTHCARE AG (DE) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203582-A1 | LYSOBACTIN AMIDES | AADAT, HAMP, DLST | OR51E2 4134/4885GLRA1 1306/4885SLC6A9 1098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.